Aizer Ayal A, Arvold Nils D, Catalano Paul, Claus Elizabeth B, Golby Alexandra J, Johnson Mark D, Al-Mefty Ossama, Wen Patrick Y, Reardon David A, Lee Eudocia Q, Nayak Lakshmi, Rinne Mikael L, Beroukhim Rameen, Weiss Stephanie E, Ramkissoon Shakti H, Abedalthagafi Malak, Santagata Sandro, Dunn Ian F, Alexander Brian M
Harvard Radiation Oncology Program, Brigham and Women's Hospital, Boston, Massachusetts (A.A.A.); Dana-Farber/Brigham and Women's Cancer Center, Boston, Massachusetts (N.D.A., B.M.A.); Department of Biostatistics, Dana-Farber Cancer Institute, Boston, Massachusetts (P.C.); Department of Neurosurgery, Brigham and Women's Hospital, Boston, Massachusetts (E.B.C., A.J.G., M.D.J., O.A-M., I.F.D.); Center for Neuro-Oncology, Dana-Farber/Brigham and Women's Cancer Center, Boston, Massachusetts (P.Y.W., D.A.R., E.Q.L., L.N., M.L.R., R.B.); Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania (S.E.W.); Department of Pathology, Brigham and Women's Hospital, Boston, Massachusetts (S.H.R., S.S., M.A.).
Neuro Oncol. 2014 Nov;16(11):1547-53. doi: 10.1093/neuonc/nou098. Epub 2014 Jun 2.
The impact of adjuvant radiation in patients with atypical meningioma remains poorly defined. We sought to determine the impact of adjuvant radiation therapy in this population.
We identified 91 patients with World Health Organization grade II (atypical) meningioma managed at Dana-Farber/Brigham and Women's Cancer Center between 1997 and 2011. A propensity score model incorporating age at diagnosis, gender, Karnofsky performance status, tumor location, tumor size, reason for diagnosis, and era of treatment was constructed using logistic regression for the outcome of receipt versus nonreceipt of radiation therapy. Propensity scores were then used as continuous covariates in a Cox proportional hazards model to determine the adjusted impact of adjuvant radiation therapy on both local recurrence and the combined endpoint of use of salvage therapy and death due to progressive meningioma.
The median follow-up in patients without recurrent disease was 4.9 years. After adjustment for pertinent confounding variables, radiation therapy was associated with decreased local recurrence in those undergoing gross total resection (hazard ratio, 0.25; 95% CI, 0.07-0.96; P = .04). No differences in overall survival were seen in patients who did and did not receive radiation therapy.
Patients who have had a gross total resection of an atypical meningioma should be considered for adjuvant radiation therapy given the improvement in local control. Multicenter, prospective trials are required to definitively evaluate the potential impact of radiation therapy on survival in patients with atypical meningioma.
辅助放疗对非典型脑膜瘤患者的影响仍不明确。我们试图确定辅助放疗对该人群的影响。
我们确定了1997年至2011年间在丹娜法伯/布列根和妇女癌症中心接受治疗的91例世界卫生组织二级(非典型)脑膜瘤患者。使用逻辑回归分析构建了一个倾向评分模型,该模型纳入了诊断时的年龄、性别、卡诺夫斯基表现状态、肿瘤位置、肿瘤大小、诊断原因和治疗时代,以分析接受放疗与未接受放疗这一结果。然后,倾向评分被用作Cox比例风险模型中的连续协变量,以确定辅助放疗对局部复发以及挽救治疗的使用和因进行性脑膜瘤死亡的联合终点的调整影响。
无复发病例患者的中位随访时间为4.9年。在对相关混杂变量进行调整后,放疗与接受全切除患者的局部复发减少相关(风险比,0.25;95%可信区间,0.07 - 0.96;P = 0.04)。接受放疗和未接受放疗的患者在总生存率方面没有差异。
鉴于局部控制有所改善,对于非典型脑膜瘤已进行全切除的患者应考虑辅助放疗。需要多中心前瞻性试验来明确评估放疗对非典型脑膜瘤患者生存的潜在影响。